Juliet C. Gray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juliet C. Gray has a total of 371 co-authors. Here are the top co-authors by number of shared publications:
- Lynley V. Marshall
Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
69 shared publications - Darren Hargrave
UCL Great Ormond Street Institute of Child Health, University College London, London, UK
68 shared publications - Michael Hubank
Royal Marsden Hospital, London, United Kingdom
68 shared publications - Richard G. Grundy
The Children’s Brain Tumour Research Centre, University of Nottingham, Nottingham, UK
68 shared publications - Thomas S. Jacques
Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
68 shared publications - John Anderson
University College London, Institute of Child Health
63 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2200
Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts
Background/Objectives: Survival outcomes with IL-2-free dinutuximab beta (DB) treatment strategies with and without 13-cis-retinoic acid (RA) have not been directly compared in a randomized study. We compared event-free survival (EFS) and overall survival (OS) between two study-defined cohorts with relapsed or refractory neuroblastoma receiving DB with or without RA. Methods: We retrospectively reanalyzed individual patient data from APN311-304 study (DB without RA, n = 36) and the experimental arm of APN311-202 V3 study (DB plus RA, n = 44). Eligibility and time zero were harmonized, and overlap-weighted Kaplan–Meier and Cox analyses were performed. An exploratory post-end-of-treatment landmark analysis was conducted among patients who remained alive and EFS-event-free through the landmark. Results: In the primary overlap-weighted analysis, no clear difference was detected between the cohorts for event-free survival (EFS; hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.31–2.73) or overall survival (OS; HR, 1.95; 95% CI, 0.46–8.20). Cohort-specific effective sample sizes were 10.15 for no RA and 15.30 for RA versus nominal sizes of 36 and 44, respectively. Exploratory conditional landmark estimates were also imprecise for EFS (HR, 1.24; 95% CI, 0.37–4.12) and OS (HR, 0.44; 95% CI, 0.07–2.71). Conclusions: This exploratory comparison did not provide evidence of more favorable EFS or OS in the RA cohort than in the no-RA cohort. However, the estimates were highly imprecise and compatible with clinically important benefit or harm. The findings should not be interpreted as evidence of equivalence or as evidence that RA provides no benefit and should not alone guide continuation or omission of RA. Because RA use was perfectly aligned with the source study, the comparison cannot isolate a causal RA effect.
- 29 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2200
Open AccessSurvival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts
Background/Objectives: Survival outcomes with IL-2-free dinutuximab beta (DB) treatment strategies with and without 13-cis-retinoic acid (RA) have not been directly compared in a randomized study. We compared event-free survival (EFS) and overall survival (OS) between two study-defined cohorts with relapsed or refractory neuroblastoma receiving DB with or without RA. Methods: We retrospectively reanalyzed individual patient data from APN311-304 study (DB without RA, n = 36) and the experimental arm of APN311-202 V3 study (DB plus RA, n = 44). Eligibility and time zero were harmonized, and overlap-weighted Kaplan–Meier and Cox analyses were performed. An exploratory post-end-of-treatment landmark analysis was conducted among patients who remained alive and EFS-event-free through the landmark. Results: In the primary overlap-weighted analysis, no clear difference was detected between the cohorts for event-free survival (EFS; hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.31–2.73) or overall survival (OS; HR, 1.95; 95% CI, 0.46–8.20). Cohort-specific effective sample sizes were 10.15 for no RA and 15.30 for RA versus nominal sizes of 36 and 44, respectively. Exploratory conditional landmark estimates were also imprecise for EFS (HR, 1.24; 95% CI, 0.37–4.12) and OS (HR, 0.44; 95% CI, 0.07–2.71). Conclusions: This exploratory comparison did not provide evidence of more favorable EFS or OS in the RA cohort than in the no-RA cohort. However, the estimates were highly imprecise and compatible with clinically important benefit or harm. The findings should not be interpreted as evidence of equivalence or as evidence that RA provides no benefit and should not alone guide continuation or omission of RA. Because RA use was perfectly aligned with the source study, the comparison cannot isolate a causal RA effect.
- 20 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (18) , 1746-1747
Reply to: Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno
- 20 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (18) , 1746-1747
Reply to: Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Disease-specific cfDNA vs. tissue sequence variants.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Disease-specific cfDNA vs. tissue sequence variants.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 9 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Paediatric cancer specific cfDNA panel (ctPC Panel).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 9 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Paediatric cancer specific cfDNA panel (ctPC Panel).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Disease-specific diagnostic vs. relapse sequence variants.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Disease-specific diagnostic vs. relapse sequence variants.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Relapse vs. primary somatic variants.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Relapse vs. primary somatic variants.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Similarity matrix for TFBS sets.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Similarity matrix for TFBS sets.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Top relapse-specific copy number events.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
Top relapse-specific copy number events.